No BS. Gilead doesn't like being in a market where they aren't number 1. With Maci, Rio and now oral Trep they will never hold onto there $500 million dollar Letairis. Gilead doesn't want to report positive HIV sales, incredible Sovaldi sales and a loss of $100 million in PAH. Wall Street will crucify them and the stock price.
After listening to our marketing department this week, we are in complete denial and a lot of trouble.
Gilead has it's head in the sand and does not want to admit they took maci lightly. They are kicking my ass too, and I did well last year!
Quit complaining, you all agreed on the goal, I saw all the heads nodding at the meeting when they asked "is this goal doable?" Then you all cheered and clapped and screamed loudly.
Merck pays $1B to buy into Bayer's cardio future May 6, 2014 | By Damian Garde SHARE TOOLS Comment Print Contact Author Reprint Merck ($MRK) plans to use the proceeds of its planned $14.2 billion consumer business sale to Bayer to beef up its pipeline, and the in-transition pharma giant isn't wasting any time, signing a billion-dollar deal with its new partner in a move to get its hands on some new cardiovascular drugs. Under the agreement, Merck will hand over $1 billion up front to split the rights to Bayer's stable of drugs that modulate soluble guanylate cyclase (sGC), an enzyme tied to the widening of blood vessels. That includes ex-U.S. rights to Adempas, Bayer's FDA-approved treatment for pulmonary arterial hypertension, and stateside rights to vericiguat, a Phase II sGC modulator under development for worsening heart failure. Merck is on the line for another $1.1 billion in milestone payments tied to collective sales of the whole franchise, Bayer said. Merck also gets opt-in rights on the rest of Bayer's early-stage sGC drugs and has agreed to make its similar candidates available under the same terms. The two plan to share costs and profits on all co-developed treatments along the way. Read more: Merck pays $1B to buy into Bayer's cardio future - FierceBiotech http://www.fiercebiotech.com/story/merck-pays-1b-buy-bayers-cardio-future/2014-05-06#ixzz31Xq8cRoQ Subscribe at FierceBiotech
